This week, we will discuss the use of LLMs for the diagnosis of complex nephrology cases. Can AI help nephrologists nail the correct diagnosis?
MERCURI-2 reports that dapagliflozin cuts postoperative AKI after cardiac surgery, but the headline result is mostly a urine-output story, not a creatinine one. That matters: urine output after surgery is easily swayed by anesthesia, fluid shifts, vasopressors, and a diuretic drug in the mix. Until dapagliflozin shows it protects kidney function, not just urine output.
This week, we will discuss SODaBIC trial: with ICU acidosis driven by multiple overlapping mechanisms, is bicarbonate infusion supported by robust evidence, or does it persist mainly out of habit rather than physiology?
FIND-CKD extends finerenone beyond diabetic kidney disease, showing slower eGFR decline and sustained albuminuria reduction in non-diabetic CKD. While the benefits are modest and cardiovascular effects remain uncertain, the trial opens the door to broader use of nsMRAs and raises important questions about combination therapy with SGLT2 inhibitors.
MERCURI-2 reports that dapagliflozin cuts postoperative AKI after cardiac surgery, but the headline result is mostly a urine-output story, not a creatinine one. That matters: urine output after surgery is easily swayed by anesthesia, fluid shifts, vasopressors, and a diuretic drug in the mix. Until dapagliflozin shows it protects kidney function, not just urine output.
Is finerenone ready to move beyond diabetes?
The FIND-CKD phase 3 arrived from the #ERA26 and is the first one to show kidney protection with finerenone in non-diabetic CKD.
The next challenge is no longer whether finerenone belongs in non-diabetic CKD, but how to best combine with the rest of the pillars to maximize protection.
Check out the newest VA created by our intern Raquel Barba
¿Está la finerenona lista para ir más allá de la diabetes?
El estudio FIND-CKD recien llegado del #ERA26, es el primer ensayo fase 3 que demuestra protección renal con finerenona en pacientes con ERC no diabética.
El siguiente reto ya no es si la finerenona tiene un lugar en la ERC no diabética, sino cómo combinarla de la mejor manera con el resto de los pilares del tratamiento para maximizar la protección renal.
No se pierdan el nuevo Visual Abstract creado por nuestra interna Raquel Barba
